This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (311)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Diabetes Mellitus  • Hypertension  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

The STOP-NIDDM Trial

Jean-Louis Chiasson, MD; Robert G. Josse, MBBS; Ramon Gomis, MD; Markolf Hanefeld, DSC; Avraham Karasik, MD; Markku Laakso, MD; for The STOP-NIDDM Trial Research Group

JAMA. 2003;290:486-494.

Context  The worldwide explosive increase in type 2 diabetes mellitus and its cardiovascular morbidity are becoming major health concerns.

Objective  To evaluate the effect of decreasing postprandial hyperglycemia with acarbose, an -glucosidase inhibitor, on the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance (IGT).

Design, Setting, and Participants  International, multicenter double-blind, placebo-controlled, randomized trial, undertaken in hospitals in Canada, Germany, Austria, Norway, Denmark, Sweden, Finland, Israel, and Spain from July 1998 through August 2001. A total of 1429 patients with IGT were randomized with 61 patients (4%) excluded because they did not have IGT or had no postrandomization data, leaving 1368 patients for a modified intent-to-treat analysis. Both men (49%) and women (51%) participated with a mean (SD) age of 54.5 (7.9) years and body mass index of 30.9 (4.2). These patients were followed up for a mean (SD) of 3.3 (1.2) years.

Intervention  Patients with IGT were randomized to receive either placebo (n = 715) or 100 mg of acarbose 3 times a day (n = 714).

Main Outcome Measures  The development of major cardiovascular events (coronary heart disease, cardiovascular death, congestive heart failure, cerebrovascular event, and peripheral vascular disease) and hypertension (140/90 mm Hg).

Results  Three hundred forty-one patients (24%) discontinued their participation prematurely, 211 in the acarbose-treated group and 130 in the placebo group; these patients were also followed up for outcome parameters. Decreasing postprandial hyperglycemia with acarbose was associated with a 49% relative risk reduction in the development of cardiovascular events (hazard ratio [HR], 0.51; 95% confidence interval [CI]; 0.28-0.95; P = .03) and a 2.5% absolute risk reduction. Among cardiovascular events, the major reduction was in the risk of myocardial infarction (HR, 0.09; 95% CI, 0.01-0.72; P = .02). Acarbose was also associated with a 34% relative risk reduction in the incidence of new cases of hypertension (HR, 0.66; 95% CI, 0.49-0.89; P = .006) and a 5.3% absolute risk reduction. Even after adjusting for major risk factors, the reduction in the risk of cardiovascular events (HR, 0.47; 95% CI, 0.24-0.90; P = .02) and hypertension (HR, 0.62; 95% CI, 0.45-0.86; P = .004) associated with acarbose treatment was still statistically significant.

Conclusion  This study suggests that treating IGT patients with acarbose is associated with a significant reduction in the risk of cardiovascular disease and hypertension.

Author Affiliations: Research Centre, Centre Hospitalier de l'Université de Montréal–Hôtel-Dieu and Department of Medicine, Université de Montréal, Montreal, Quebec (Dr Chiasson); Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario (Dr Josse); Diabetes Unit, Hospital Clinic, Universitari de Barcelona, Barcelona, Spain (Dr Gomis); Centre for Clinical Studies GWT, Dresden Technical University, Dresden, Germany (Handefeld); Institute of Endocrinology, Chaim Sheba Medical Centre, Tel Hashomer, Israel (Dr Karasik); and Department of Medicine, University of Kuopio, Kuopio, Finland (Dr Laakso).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of cereal test breakfasts differing in glycemic index and content of indigestible carbohydrates on daylong glucose tolerance in healthy subjects
Nilsson et al.
Am. J. Clin. Nutr. 2008;87:645-654.
ABSTRACT | FULL TEXT  

Hydroxypropylmethylcellulose and Methylcellulose Consumption Reduce Postprandial Insulinemia in Overweight and Obese Men and Women
Maki et al.
J. Nutr. 2008;138:292-296.
ABSTRACT | FULL TEXT  

Natural History of Cardiovascular Disease in Patients With Diabetes: Role of hyperglycemia
Milicevic et al.
Diabetes Care 2008;31:S155-S160.
ABSTRACT | FULL TEXT  

New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Inzucchi and McGuire
Circulation 2008;117:574-584.
ABSTRACT | FULL TEXT  

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart
Anselmino et al.
Eur Heart J 2008;29:177-184.
ABSTRACT | FULL TEXT  

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
Lund et al.
Eur J Endocrinol 2008;158:35-46.
ABSTRACT | FULL TEXT  

Glucose metabolism and hyperglycemia
Giugliano et al.
Am. J. Clin. Nutr. 2008;87:217S-222S.
ABSTRACT | FULL TEXT  

Lessons From the Avandia Controversy: A new paradigm for the development of drugs to treat type 2 diabetes
Misbin
Diabetes Care 2007;30:3141-3144.
FULL TEXT  

Type 1 Diabetes and Glucose Monitoring
Bloomgarden
Diabetes Care 2007;30:2965-2971.
FULL TEXT  

Diabetes Treatment, Part 2: Oral Agents for Glycemic Management
Fowler
Clin. Diabetes 2007;25:131-134.
FULL TEXT  

Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes
Williams et al.
Am. J. Clin. Nutr. 2007;86:124-130.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT  

High-Viscosity Hydroxypropylmethylcellulose Blunts Postprandial Glucose and Insulin Responses
Maki et al.
Diabetes Care 2007;30:1039-1043.
ABSTRACT | FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al.
Jellinger et al.
Diabetes Care 2007;30:e16-e17.
FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Jellinger, Lebovitz, and Davidson
Davidson
Diabetes Care 2007;30:e18-e20.
FULL TEXT  

Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care
Nathan et al.
Diabetes Care 2007;30:753-759.
FULL TEXT  

Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
Wilcox et al.
Stroke 2007;38:865-873.
ABSTRACT | FULL TEXT  

Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach
Gerstein
Diabetes Care 2007;30:432-434.
FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al.
Parkin and Davidson
Diabetes Care 2007;30:192-193.
FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Cryer, Porta and Trento, and Parkin and Davidson
Nathan and On Behalf of the ADA/DASD Consensus Group
Diabetes Care 2007;30:194-196.
FULL TEXT  

Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart
Bartnik et al.
Heart 2007;93:72-77.
ABSTRACT | FULL TEXT  

Prediction of Postprandial Glycemic Exposure: Utility of fasting and 2-h glucose measurements alone and in combination with assessment of body composition, fitness, and strength
Cohen et al.
Diabetes Care 2006;29:2708-2713.
ABSTRACT | FULL TEXT  

Almonds Decrease Postprandial Glycemia, Insulinemia, and Oxidative Damage in Healthy Individuals
Jenkins et al.
J. Nutr. 2006;136:2987-2992.
ABSTRACT | FULL TEXT  

Glycemic treatment in type 1 and type 2 diabetes.
Bloomgarden
Diabetes Care 2006;29:2549-2555.
FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Care 2006;29:1963-1972.
FULL TEXT  

Lowering dietary glycemic load for weight control and cardiovascular health: a matter of quality.
Liu
Arch Intern Med 2006;166:1438-1439.
FULL TEXT  

Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular risk.
Gerich
The Diabetes Educator 2006;32:513-522.
ABSTRACT | FULL TEXT  

Combined Treatment With Exercise Training and Acarbose Improves Metabolic Control and Cardiovascular Risk Factor Profile in Subjects With Mild Type 2 Diabetes
Wagner et al.
Diabetes Care 2006;29:1471-1477.
ABSTRACT | FULL TEXT  

Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis: A 7-year observational study
Oomichi et al.
Diabetes Care 2006;29:1496-1500.
ABSTRACT | FULL TEXT  

All Pre-Diabetes Is Not the Same: Metabolic and Vascular Risks of Impaired Fasting Glucose at 100 Versus 110 mg/dl: The Screening for Impaired Glucose Tolerance Study 1 (SIGT 1).
Phillips et al.
Diabetes Care 2006;29:1405-1407.
FULL TEXT  

Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes
Haffner
Eur Heart J Suppl 2006;8:B20-B25.
ABSTRACT | FULL TEXT  

Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes
Monnier et al.
JAMA 2006;295:1681-1687.
ABSTRACT | FULL TEXT  

Influence of Metabolic Syndrome and General Obesity on the Risk of Ischemic Stroke
Chen et al.
Stroke 2006;37:1060-1064.
ABSTRACT | FULL TEXT  

Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice
Liao et al.
Cardiovasc Res 2006;70:107-116.
ABSTRACT | FULL TEXT  

Postprandial Blood Glucose Is a Stronger Predictor of Cardiovascular Events Than Fasting Blood Glucose in Type 2 Diabetes Mellitus, Particularly in Women: Lessons from the San Luigi Gonzaga Diabetes Study
Cavalot et al.
J. Clin. Endocrinol. Metab. 2006;91:813-819.
ABSTRACT | FULL TEXT  

Effects of a Single Administration of Acarbose on Postprandial Glucose Excursion and Endothelial Dysfunction in Type 2 Diabetic Patients: A Randomized Crossover Study
Shimabukuro et al.
J. Clin. Endocrinol. Metab. 2006;91:837-842.
ABSTRACT | FULL TEXT  

Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes
Woerle et al.
Am. J. Physiol. Endocrinol. Metab. 2006;290:E67-E77.
ABSTRACT | FULL TEXT  

Review: {alpha} glucosidase inhibitors improve glycaemic control but have uncertain effects on patient-important outcomes in type 2 diabetes
Isley
Evid. Based Med. 2005;10:174-174.
FULL TEXT  

Laparoscopic Gastric Banding Prevents Type 2 Diabetes and Arterial Hypertension and Induces Their Remission in Morbid Obesity: A 4-year case-controlled study
Pontiroli et al.
Diabetes Care 2005;28:2703-2709.
ABSTRACT | FULL TEXT  

Postprandial Hyperglycemia Is a Better Predictor of the Progression of Diabetic Retinopathy Than HbA1c in Japanese Type 2 Diabetic Patients
Shiraiwa et al.
Diabetes Care 2005;28:2806-2807.
FULL TEXT  

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy et al.
Circulation 2005;112:2735-2752.
FULL TEXT  

Differences in Cardiovascular Risk Factors, Insulin Resistance, and Insulin Secretion in Individuals With Normal Glucose Tolerance and in Subjects With Impaired Glucose Regulation: The Telde Study
Novoa et al.
Diabetes Care 2005;28:2388-2393.
ABSTRACT | FULL TEXT  

Glycated and Oxidized Protein Degradation Products Are Indicators of Fasting and Postprandial Hyperglycemia in Diabetes
Ahmed et al.
Diabetes Care 2005;28:2465-2471.
ABSTRACT | FULL TEXT  

Enteral Nutritional Support and Use of Diabetes-Specific Formulas for Patients With Diabetes: A systematic review and meta-analysis
Elia et al.
Diabetes Care 2005;28:2267-2279.
ABSTRACT | FULL TEXT  

Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects
Chaikomin et al.
Am. J. Physiol. Endocrinol. Metab. 2005;289:E504-E507.
ABSTRACT | FULL TEXT  

Metformin's contraindications should be contraindicated
McCormack et al.
CMAJ 2005;173:502-504.
FULL TEXT  

Changing the Definition of Impaired Fasting Glucose: Impact on the classification of individuals and risk definition
Vaccaro and Riccardi
Diabetes Care 2005;28:1786-1788.
ABSTRACT | FULL TEXT  

{alpha}-Glucosidase Inhibitors for Patients With Type 2 Diabetes: Response to van de Laar et al.
Hanefeld et al.
Diabetes Care 2005;28:1840-1840.
FULL TEXT  

Oral Agents for Type 2 Diabetes: An Update
Kimmel and Inzucchi
Clin. Diabetes 2005;23:64-76.
ABSTRACT | FULL TEXT  

Primary Prevention of Cardiovascular Disease in Pre-Diabetes: The glass is half full and half empty
Dagogo-Jack
Diabetes Care 2005;28:971-972.
FULL TEXT  

Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes
Ceriello et al.
Diabetes Care 2005;28:632-637.
ABSTRACT | FULL TEXT  

A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes
Padwal et al.
Diabetes Care 2005;28:736-744.
ABSTRACT | FULL TEXT  

Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes
Ceriello et al.
Diabetes Care 2005;28:266-272.
ABSTRACT | FULL TEXT  

Prevalence of Abnormal Glucose Tolerance Following a Transient Ischemic Attack or Ischemic Stroke
Kernan et al.
Arch Intern Med 2005;165:227-233.
ABSTRACT | FULL TEXT  

Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care
Feig et al.
CMAJ 2005;172:177-180.
FULL TEXT  

Postprandial Hyperglycemia and Diabetes Complications: Is It Time to Treat?
Ceriello
Diabetes 2005;54:1-7.
ABSTRACT | FULL TEXT  

Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes
Tushuizen et al.
Postgrad. Med. J. 2005;81:1-6.
ABSTRACT | FULL TEXT  

Pharmacologic Prevention or Delay of Type 2 Diabetes Mellitus
Anderson
The Annals of Pharmacotherapy 2005;39:102-109.
ABSTRACT | FULL TEXT  

Postprandial Glucose Regulation and Diabetic Complications
Ceriello et al.
Arch Intern Med 2004;164:2090-2095.
ABSTRACT | FULL TEXT  

Is Nondiabetic Hyperglycemia a Risk Factor for Cardiovascular Disease?: A Meta-analysis of Prospective Studies
Levitan et al.
Arch Intern Med 2004;164:2147-2155.
ABSTRACT | FULL TEXT  

Effects of Glycemic Control on Diabetes Complications and on the Prevention of Diabetes
Skyler
Clin. Diabetes 2004;22:162-166.
ABSTRACT | FULL TEXT  

Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus
Esposito et al.
Circulation 2004;110:214-219.
ABSTRACT | FULL TEXT  

Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction - scientifically credible: Reply
Hanefeld
Eur Heart J 2004;25:1179-1180.
FULL TEXT  

Differences in Insulin Resistance in Nondiabetic Subjects With Isolated Impaired Glucose Tolerance or Isolated Impaired Fasting Glucose
Festa et al.
Diabetes 2004;53:1549-1555.
ABSTRACT | FULL TEXT  

Glycemic Treatment: Control of glycemia
Bloomgarden
Diabetes Care 2004;27:1227-1234.
FULL TEXT  

Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited
Ceriello and Motz
Arterioscler. Thromb. Vasc. Bio. 2004;24:816-823.
ABSTRACT | FULL TEXT  

Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance
Hanefeld et al.
Stroke 2004;35:1073-1078.
ABSTRACT | FULL TEXT  

Follow-up Report on the Diagnosis of Diabetes Mellitus
Expert Committee on the Diagnosis and Classificati
Clin. Diabetes 2004;22:71-79.
FULL TEXT  

Preventing Type II Diabetes Mellitus
Prisant
J Clin Pharmacol 2004;44:406-413.
ABSTRACT | FULL TEXT  

ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2004;9:3-3.
FULL TEXT  

Follow-up Report on the Diagnosis of Diabetes Mellitus
Diabetes Spectr. 2004;17:51-59.
FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Rosenthal
JAMA 2003;290:3066-3066.
FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Gonzalez-Clemente et al.
JAMA 2003;290:3067-3067.
FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Kaiser and Sawicki
JAMA 2003;290:3066-3066.
FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Bridges
JAMA 2003;290:3066-3067.
FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance--Reply
Chiasson et al.
JAMA 2003;290:3067-3069.
FULL TEXT  

Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management
Hurst and Lee
ANN INTERN MED 2003;139:824-834.
ABSTRACT | FULL TEXT  

Follow-up Report on the Diagnosis of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classifi
Diabetes Care 2003;26:3160-3167.
FULL TEXT  

Acarbose Reduces CVD and Hypertension Risk in Patients with Impaired Glucose Tolerance
Journal Watch Cardiology 2003;2003:5-5.
FULL TEXT  

JournalScan
Malik
Heart 2003;89:1279-1280.
FULL TEXT  

A Niche for Acarbose in Early Type 2 Diabetes?
JWatch General 2003;2003:1-1.
FULL TEXT